Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc./ US09061G1013 /
BM8
03/06/2024 07:57:15
|
Chg.
+0.7600
|
Volume |
Bid19:44:53 |
Demandez à19:44:53 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
69.3800EUR
|
+1.11%
|
- Chiffrre d'affaires: - |
69.9600Bid taille: 320 |
70.0800Ask la taille: 320 |
13.31 Mrd.EUR |
- |
- |
Description de l'entreprise
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
Conseil d'administration & Conseil de surveillance
PDG |
Jean-Jacques Bienaimé |
Conseil d'administration |
Brian Mueller, Amy Wireman, Dr. Brinda Balakrishnan, Dr. C. Greg Guyer, G. Eric Davis, Henry J. Fuchs, Jeff Ajer, Philip Lo Scalzo |
Conseil de surveillance |
Jean-Jacques Bienaimé, David Pyott, Dr. Dennis J. Slamon, Dr. Elaine J. Heron, Dr. V. Bryan Lawlis, Elizabeth Anderson, Mark Alles, Maykin Ho, Richard A. Meier, Robert Hombach, Willard H. Dere |
Données de l'entreprise
Nom: |
Biomarin Pharmaceutical Inc. |
Adresse: |
770 Lindaro Street,San Rafael, California 94901, USA |
Téléphone: |
+1-415-506-6700 |
Fax: |
+1-415-3827889 |
Courriel: |
-
|
Internet: |
www.bmrn.com/ |
Industrie: |
Healthcare |
Secteur: |
Pharmaceutical Industry |
Sous-secteur: |
Pharmaceuticals |
Fin de l'exercice financier: |
31/12 |
Flotte libre: |
58.89% |
IPO date: |
01/07/1999 |
Relations avec les investisseurs
Nom: |
Traci McCarty |
Téléphone IR: |
+1-415-455-7558 |
IR-Fax: |
- |
E-mail IR: |
IR@BMRN.com
|
Principaux actionnaires
Freefloat |
|
58.89% |
PRIMECAP Management Company |
|
9.67% |
The Vanguard Group |
|
8.88% |
Dodge & Cox |
|
8.05% |
BlackRock, Inc. |
|
7.62% |
Capital Research Global Investors |
|
6.89% |